The guideline of prevention and treatment for chronic hepatitis B (2010 Version)

Chinese Journal of Gastroenterology

Volumn 16, Issue 6, 2011, Pages 351-366

  Jia, Jidong ^a   Li, Lanjuan ^b  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b ZHEJIANG UNIVERSITY   (China)

Author keywords

Guidebooks; Hepatitis B, chronic; Prevention; Therapy

Indexed keywords

ARTICLE; HEPATITIS B; INFECTION PREVENTION; PRACTICE GUIDELINE;

EID: 84858969335     PISSN: 10087125     EISSN: None     Source Type: Journal    
DOI: 10.3969/j.issn.1008-7125.2011.06.009     Document Type: Article

References (114)

1. 2005, 13 (12): 881-891.
2. Seeger C, Mason W S. Hepatitis B virus biology. Microbiol Mol Biol Rev, 2000, 64 (1): 51-68.
3. Scaglioni P P, Melegari M, Wands J R. Biologic properties of hepatitis B viral genomes with mutations in the precore promoter and precore open reading frame. Virology, 1997, 233 (2): 374-381.
4. Tran T T, Trinh T N, Abe K. New complex recombinant genotype of hepatitis B virus identified in Vietnam. J Virol, 2008, 82 (11): 5657-5663.
5. Olinger C M, Jutavijittum P, Hübschen J M, et al. Possible new hepatitis B virus genotype, southeast Asia. Emerg Infect Dis, 2008, 14 (11): 1777-1780.
6. Chu C J, Hussain M, Lok A S. Hepatitis B virus genotype B is associated with earlier HBeAg seroconversion compared with hepatitis B virus genotype C. Gastroenterology, 2002, 122 (7): 1756-1762.
7. Chu C M, Liaw Y F. Genotype C hepatitis B virus infection is associated with a higher risk of reactivation of hepatitis B and progression to cirrhosis than genotype B: a longitudinal study of hepatitis B e antigen-positive patients with normal aminotransferase levels at baseline. J Hepatol, 2005, 43 (3): 411-417.
8. Yu M W, Yeh S H, Chen P J, et al. Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men. J Natl Cancer Inst, 2005, 97 (4): 265-272.
9. Zhang H W, Yin J H, Li Y T, et al. Risk factors for acute hepatitis B and its progression to chronic hepatitis in Shanghai, China. Gut, 2008, 57 (12): 1713-1720.
10. Hou J, Schilling R, Janssen H L, et al. Genetic characteristics of hepatitis B virus genotypes as a factor for interferon-induced HBeAg clearance. J Med Virol, 2007, 79 (8): 1055-1063.
11. Jardi R, Rodriguez-Frias F, Schaper M, et al. Analysis of hepatitis B genotype changes in chronic hepatitis B infection: Influence of antiviral therapy. J Hepatol, 2008, 49 (5): 695-701.
12. Liu C J, Kao J H. Genetic variability of hepatitis B virus and response to antiviral therapy. Antivir Ther, 2008, 13 (5): 613-624.
13. Ganem D, Prince A M. Hepatitis B virus infection-natural history and clinical consequences. N Engl J Med, 2004,350(11): 1118-1129.
14. World Health Organization. Hepatitis B. (Revised August 2008). [2010-12-9]. http://www.Who.int/mediacentre/factsheets/fs204/en/
15. Liang X, Bi S, Yang W, et al. Epidemiological serosurvey of hepatitis B in China-declining HBV prevalence due to hepatitis B vaccination. Vaccine, 2009, 27 (47): 6550-6557.
16. Liang X, Bi S, Yang W, et al. Evaluation of the impact of hepatitis B vaccination among children born during 1992-2005 in China. J Infect Dis, 2009, 200 (1): 39-47.
17. Lu F M, Zhuang H. Management of hepatitis B in China. Chin Med J (Engl), 2009, 122 (1): 3-4.
18. Mast E E, Weinbaum C M, Fiore A E, et al; Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC). A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults. MMWR Recomm Rep, 2006, 55 (RR-16): 1-33.
19. World Health Organization. Hepatitis B. [2010-12-9]. http://www.who.int/csr/disease/hepatitis/ HepatitisB_whocdscsrlyo2002_2.pdf
20. Lai C L, Ratziu V, Yuen M F, et al. Viral hepatitis B. Lancet, 2003, 362 (9401): 2089-2094.
21. Liaw Y F. Natural history of chronic hepatitis B virus infection and long-term outcome under treatment. Liver Int, 2009, 29 (Suppl 1): 100-107.
22. Hui C K, Leung N, Yuen S T, et al; Hong Kong Liver Fibrosis Study Group. Natural history and disease progression in Chinese chronic hepatitis B patients in immune-tolerant phase. Hepatology, 2007, 46 (2): 395-401.
23. McMahon B J. The natural history of chronic hepatitis B virus infection. Hepatology, 2009, 49 (5 Suppl): S45-S55.
24. Liaw Y F. Hepatitis flares and hepatitis B e antigen seroconversion: implication in anti-hepatitis B virus therapy. J Gastroenterol Hepatol, 2003, 18 (3): 246-252.
25. Chu C M, Hung S J, Lin J, et al. Natural history of hepatitis B e antigen to antibody seroconversion in patients with normal serum aminotransferase levels. Am J Med, 2004, 116 (12): 829-834.
26. Fattovich G, Brollo L, Alberti A, et al. Long-term follow-up of anti-HBe-positive chronic active hepatitis B. Hepatology, 1988, 8 (6): 1651-1654.
27. Brunetto M R, Oliveri F, Rocca G, et al. Natural course and response to interferon of chronic hepatitis B accompanied by antibody to hepatitis B e antigen. Hepatology, 1989, 10 (2): 198-202.
28. Di Marco V, Lo Iacono O, Cammà C, et al. The long-term course of chronic hepatitis B. Hepatology, 1999, 30 (1): 257-264.
29. Chu C M, Liaw Y F. Hepatitis B virus-related cirrhosis: natural history and treatment. Semin Liver Dis, 2006, 26 (2): 142-152.
30. Chen Y C, Chu C M, Yeh C T, et al. Natural course following the onset of cirrhosis in patients with chronic hepatitis B: a long-term follow-up study. Hepatol Int, 2007, 1 (1): 267-273.
31. Hsu Y S, Chien R N, Yeh C T, et al. Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology, 2002, 35 (6): 1522-1527.
32. Chou Y C, Yu M W, Wu C F, et al. Temporal relationship between hepatitis B virus enhancer II/basal core promoter sequence variation and risk of hepatocellular carcinoma. Gut, 2008, 57 (1): 91-97.
33. Chen C J, Yang H I, Su J, et al; REVEAL-HBV Study Group. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA, 2006, 295 (1): 65-73.
34. Yang H I, Lu S N, Liaw Y F, et al; Taiwan Community-Based Cancer Screening Project Group. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med, 2002, 347 (3): 168-174.
35. Iloeje U H, Yang H I, Su J, et al; Risk Evaluation of Viral Load Elevation and Associated Liver Disease/Cancer-In HBV (the REVEAL-HBV) Study Group. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology, 2006, 130 (3): 678-686.
36. Tai D I, Chen C H, Chang T T, et al. Eight-year nationwide survival analysis in relatives of patients with hepatocellular carcinoma: role of viral infection. J Gastroenterol Hepatol, 2002, 17 (6): 682-689.
37. 2002.
38. 2003, 24 (5): 362-365.
39. 1990, 4: 485-488.
40. Center for Disease Prevention and Control. Breastfeeding. [2010-12-8]. http://www.cdc.gov/breastfeeding/disease/hepatitis.htm
41. World Health Organization. Hepatitis B and breastfeeding. [2010-12-8]. http://www.who.int/childadolescent_health/documents/pdfs/ hepatitis_b_and_breastfeeding.pdf
42. Zanetti A R, Mariano A, Romanò L, et al; Study Group. Long-term immunogenicity of hepatitis B vaccination and policy for booster: an Italian multicentre study. Lancet, 2005, 366 (9494): 1379-1384.
43. John T J, Cooksley G; Steering Committee for the Prevention and Control of Infectious Diseases in Asia. Hepatitis B vaccine boosters: is there a clinical need in high endemicity populations? J Gastroenterol Hepatol, 2005, 20 (1): 5-10.
44. U.S. Public Health Service. Updated U.S. public health service guidelines for the management of occupational exposures to HBV, HCV, and HIV and recommendations for postexposure prophylaxis. MMWR Recomm Rep, 2001, 50 (RR-11): 1-52.
45. 2000, 8 (6): 324-329.
46. Pawlotsky J M, Dusheiko G, Hatzakis A, et al. Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: recommendations for a standardized approach. Gastroenterology, 2008, 134 (2): 405-415.
47. Shaheen A A, Wan A F, Myers R P. FibroTest and FibroScan for the prediction of hepatitis C-related fibrosis: a systematic review of diagnostic test accuracy. Am J Gastroenterol, 2007, 102 (11): 2589-2600.
48. Scott D R, Levy M T. Liver transient elastography (Fibroscan): a place in the management algorithms of chronic viral hepatitis. Antivir Ther, 2010, 15 (1): 1-11.
49. Lok A S, McMahon B J. Chronic hepatitis B: update 2009. Hepatology, 2009, 50 (3): 661-662.
50. Lin S M, Yu M L, Lee C M, et al. Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma. J Hepatol, 2007, 46 (1): 45-52.
51. Manesis E K, Hadziyannis S J. Interferon alpha treatment and retreatment of hepatitis B e antigen-negative chronic hepatitis B. Gastroenterology, 2001, 121 (1): 101-109.
52. Lau G K, Piratvisuth T, Luo K X, et al; Peginterferon Alfa2a HBeAg-Positive Chronic Hepatitis B Study Group. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med, 2005, 352 (26): 2682-2695.
53. Piratvisuth T, Lau G, Chao Y C, et al. Sustained response to peginterferon alfa-2a (40 kD) with or without lamivudine in Asian patients with HBeAg-positive and HBeAg-negative chronic hepatitis B. Hepatol Int, 2008, 2 (1): 102-110.
54. Chan H L, Leung N W, Hui A Y, et al. A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-alpha2b and lamivudine with lamivudine alone. Ann Intern Med, 2005, 142 (4): 240-250.
55. Flink H J, van Zonneveld M, Hansen B E, et al; HBV 9901 Study Group. Treatment with Peg-interferon alpha-2b for HBeAg-positive chronic hepatitis B: HBsAg loss is associated with HBV genotype. Am J Gastroenterol, 2006, 101 (2): 297-303.
56. Buster E H, Flink H J, Cakaloglu Y, et al. Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha2b. Gastroenterology, 2008, 135 (2): 459-467.
57. Marcellin P, Lau G K, Bonino F, et al; Peginterferon Alfa2a HBeAg-Negative Chronic Hepatitis B Study Group. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med, 2004, 351 (12): 1206-1217.
58. Marcellin P, Bonino F, Lau G K, et al; Peginterferon alfa2a in HBeAg-negative Chronic Hepatitis B Study Group. Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha2a. Gastroenterology, 2009, 136 (7): 2169-2179.
59. Lok A S, McMahon B J. Chronic hepatitis B. Hepatology, 2007, 45 (2): 507-539.
60. Keeffe E B, Dieterich D T, Han S H, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update. Clin Gastroenterol Hepatol, 2006, 4 (8): 936-962.
61. Fried M W, Piratvisuth T, Lau G K, et al. HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B. Hepatology, 2008, 47 (2): 428-434.
62. Moucari R, Mackiewicz V, Lada O, et al. Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. Hepatology, 2009, 49 (4): 1151-1157.
63. Brunetto M R, Moriconi F, Bonino F, et al. Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. Hepatology, 2009, 49 (4): 1141-1150.
64. Lok A S, Lai C L, Leung N, et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology, 2003, 125 (6): 1714-1722.
65. Lai C L, Chien R N, Leung N W, et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med, 1998, 339 (2): 61-68.
66. Liaw Y F, Leung N W, Chang T T, et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterology, 2000, 119 (1): 172-180.
67. Dienstag J L, Schiff E R, Wright T L, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med, 1999, 341 (17): 1256-1263.
68. Chien R N, Liaw Y F, Atkins M. Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B. Asian Hepatitis Lamivudine Trial Group. Hepatology, 1999, 30 (3): 770-774.
69. Dienstag J L, Goldin R D, Heathcote E J, et al. Histological outcome during long-term lamivudine therapy. Gastroenterology, 2003, 124 (1): 105-117.
70. Liaw Y F, Sung J J, Chow W C, et al; Cirrhosis Asian Lamivudine Multicentre Study Group. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med, 2004, 351 (15): 1521-1531.
71. Villeneuve J P, Condreay L D, Willems B, et al. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B. Hepatology, 2000, 31 (1): 207-210.
72. Perrillo R P, Wright T, Rakela J, et al; Lamivudine North American Transplant Group. A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B. Hepatology, 2001, 33 (2): 424-432.
73. Hann H W, Fontana R J, Wright T, et al; United States Lamivudine Compassionate Use Study Group. A United States compassionate use study of lamivudine treatment in nontransplantation candidates with decompensated hepatitis B virus-related cirrhosis. Liver Transpl, 2003, 9 (1): 49-56.
74. Jonas M M, Mizerski J, Badia I B, et al; International Pediatric Lamivudine Investigator Group. Clinical trial of lamivudine in children with chronic hepatitis B. N Engl J Med, 2002, 346 (22): 1706-1713.
75. Figlerowicz M, Kowala-Piaskowska A, Filipowicz M, et al. Efficacy of lamivudine in the treatment of children with chronic hepatitis B. Hepatol Res, 2005, 31 (4): 217-222.
76. 2003, 11 (2): 103-108.
77. 2003, 42 (6): 382-387.
78. 2005, 23 (6): 387-394.
79. Marcellin P, Chang T T, Lim S G, et al; Adefovir Dipivoxil 437 Study Group. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med, 2003, 348 (9): 808-816.
80. Marcellin P, Chang T T, Lim S G, et al. Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. Hepatology, 2008, 48 (3): 750-758.
81. Hadziyannis S J, Tassopoulos N C, Heathcote E J, et al; Adefovir Dipivoxil 438 Study Group. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology, 2006, 131 (6): 1743-1751.
82. Hadziyannis S J, Tassopoulos N C, Heathcote E J, et al; Adefovir Dipivoxil 438 Study Group. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N Engl J Med, 2005, 352 (26): 2673-2681.
83. Hadziyannis S J, Tassopoulos N C, Heathcote E J, et al; Adefovir Dipivoxil 438 Study Group. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med, 2003, 348 (9): 800-807.
84. Lampertico P, Viganò M, Manenti E, et al. Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients. Gastroenterology, 2007, 133 (5): 1445-1451.
85. Rapti I, Dimou E, Mitsoula P, et al. Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B. Hepatology, 2007, 45 (2): 307-313.
86. Lampertico P, Viganò M, Manenti E, et al. Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine. Hepatology, 2005, 42 (6): 1414-1419.
87. Peters M G, Hann Hw H, Martin P, et al. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology, 2004, 126 (1): 91-101.
88. Perrillo R, Hann H W, Mutimer D, et al. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology, 2004, 126 (1): 81-90.
89. Marzano A, Lampertico P, Mazzaferro V, et al. Prophylaxis of hepatitis B virus recurrence after liver transplantation in carriers of lamivudine-resistant mutants. Liver Transpl, 2005, 11 (5): 532-538.
90. 2006, 12(5): 313-315.
91. Chang T T, Gish R G, de Man R, et al; BEHoLD AI463022 Study Group. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med, 2006, 354 (10): 1001-1010.
92. Lai C L, Shouval D, Lok A S, et al; BEHoLD AI463027 Study Group. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med, 2006, 354 (10): 1011-1020.
93. Gish R G, Lok A S, Chang T T, et al. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology, 2007, 133 (5): 1437-1444.
94. Yokosuka O, Takaguchi K, Fujioka S, et al. Long-term use of entecavir in nucleoside-naïve Japanese patients with chronic hepatitis B infection. J Hepatol, 2010, 52 (6): 791-799.
95. Sherman M, Yurdaydin C, Sollano J, et al; AI463026 BEHoLD Study Group. Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. Gastroenterology, 2006, 130 (7): 2039-2049.
96. 2006, 24 (6): 385-389.
97. 2006, 45 (11): 891-895.
98. Liaw Y F, Gane E, Leung N, et al; GLOBE Study Group. 2-Year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology, 2009, 136 (2): 486-495.
99. Lai C L, Gane E, Liaw Y F, et al; Globe Study Group. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med, 2007, 357 (25): 2576-2588.
100. Hou J, Yin Y K, Xu D, et al. Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: Results at 1 year of a randomized, double-blind trial. Hepatology, 2008, 47 (2): 447-454.
101. Zeuzem S, Gane E, Liaw Y F, et al. Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B. J Hepatol, 2009, 51 (1): 11-20.
102. 2007, 15 (5): 342-345.
103. Marcellin P, Heathcote E J, Buti M, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med, 2008, 359 (23): 2442-2455.
104. Heathcote E J, Marcellin P, Buti M, et al. Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology, 2011, 140 (1): 132-143.
105. Yuen M F, Fong D Y, Wong D K, et al. Hepatitis B virus DNA levels at week 4 of lamivudine treatment predict the 5-year ideal response. Hepatology, 2007, 46 (6): 1695-1703.
106. Keeffe E B, Zeuzem S, Koff R S, et al. Report of an international workshop: Roadmap for management of patients receiving oral therapy for chronic hepatitis B. Clin Gastroenterol Hepatol, 2007, 5 (8): 890-897.
107. Chan H L, Tang J L, Tam W, et al. The efficacy of thymosin in the treatment of chronic hepatitis B virus infection: a meta-analysis. Aliment Pharmacol Ther, 2001, 15 (12): 1899-1905.
108. Chien R N, Liaw Y F, Chen T C, et al. Efficacy of thymosin alpha 1 in patients with chronic hepatitis B: a randomized, controlled trial. Hepatology, 1998, 27 (5): 1383-1387.
109. Hui C K, Cheung W W, Zhang H Y, et al. Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy. Gastroenterology, 2006, 131 (1): 59-68.
110. 2006, 14 (9): 643-646.
111. Hung I F, Poon R T, Lai C L, et al. Recurrence of hepatitis B-related hepatocellular carcinoma is associated with high viral load at the time of resection. Am J Gastroenterol, 2008, 103 (7): 1663-1673.
112. Koda M, Nagahara T, Matono T, et al. Nucleotide analogs for patients with HBV-related hepatocellular carcinoma increase the survival rate through improved liver function. Intern Med, 2009, 48 (1): 11-17.
113. Zhang F K, Liu D G, Jia J D. Antiviral therapy for hepatitis B in special populations. Antivir Ther, 2010, 15 (8): 1067-1075.
114. Sokal E M, Kelly D, Wirth S, et al. The pharmacokinetics and safety of adefovir dipivoxil in children and adolescents with chronic hepatitis B virus infection. J Clin Pharmacol, 2008, 48 (4): 512-517.